Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose I-131 MIBG for Metastatic Neuroendocrine Tumors
NCT00037869Phase 3Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2001
- Primary completion
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iobenguane I-131 in neuroendocrine tumors (NETs), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2001; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT00037869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00037869.